Country: EU
Laboratories❯
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
Quality & Accuracy
Experience
The latest technologies
Speed &
Credibility
₾210.00
Study material: Venous blood
Response time (working day): 14
The test is done on an empty stomach: Yes
Home call service: YesSamplesSendWill be implementedOn Tuesdays,Of the daysecondHalfway!For this,SampleCentralin the laboratoryShouldTo be sentTuesday at 12:00till
It is a genetic study that evaluates Plasminogen activator inhibitor-1 (PAI-1) The 4G/5G polymorphism in the gene. This polymorphism affects the levels of the PAI-1 protein, which is involved in fibrinolysis and the blood clotting process.
PAI-1 (Plasminogen Activator Inhibitor-1) It is a protein that plays an important role in regulating blood clotting and thrombus dissolution.
The main function of PAI-1 in plasma
PAI-1 is Fibrinolysis inhibitor, that is, it inhibits the process of blood clot dissolution.
Accordingly, elevated levels of PAI-1 in plasma lead to decreased fibrinolytic activity and are associated with the development of arterial or venous thrombosis.
PAI-1 (Plasminogen Activator Inhibitor-1) The protein is synthesized by the PAI-1 gene, which is located on chromosome 7 and contains 8 introns and 9 exons.
The 4G/5G polymorphism of the gene (a guanosine deletion/insertion at position 675 of the PAI-1 gene promoter) is one of the main genetic determinants of PAI-1 levels.
Research material – Venous blood.
One of three possible outcomes is observed for the patient:
In 4G/4G homozygous patients (frequency in the European population approximately 11%) the level of PAI-1 is approximately 25% higher than in 5G/5G homozygotes.
Elevated PAI-1 levels are also found in the heterozygous 4G/5G genotype, the frequency of which in the European population is approximately 40%.
Carrying the 4G allele is associated with obesity, arterial hypertension, and a slightly increased risk of myocardial infarction.
In terms of pregnancy pathology, according to one study, the presence of 4G/4G or 4G/5G genotypes is clinically significant in the development of venous thromboembolism during pregnancy.
The presence of the 4G allele is an independent risk factor for myocardial infarction in young patients (≤45 years), especially in the presence of risk factors (tobacco use, family history of arterial hypertension and cardiovascular diseases, etc.).
In patients with coronary artery disease, the presence of the 4G/4G genotype is associated with an increased risk of sudden death.
The test is not used in isolation. The results are analyzed in conjunction with other clinical and laboratory data.
Order all analyses online
Testing process
 |  |
| Purchase a test | Submission of material |
 |  |
| Results Online | Consult a doctor |
News and promotions
